摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

4-bromo-1-methoxy-2-(methoxymethoxy)benzene | 623550-16-3

中文名称
——
中文别名
——
英文名称
4-bromo-1-methoxy-2-(methoxymethoxy)benzene
英文别名
——
4-bromo-1-methoxy-2-(methoxymethoxy)benzene化学式
CAS
623550-16-3
化学式
C9H11BrO3
mdl
——
分子量
247.089
InChiKey
TWHPNWMJJYXOSY-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    2.5
  • 重原子数:
    13
  • 可旋转键数:
    4
  • 环数:
    1.0
  • sp3杂化的碳原子比例:
    0.33
  • 拓扑面积:
    27.7
  • 氢给体数:
    0
  • 氢受体数:
    3

SDS

SDS:163cf6487665fd28378d0b3937e7c4c0
查看

上下游信息

  • 上游原料
    中文名称 英文名称 CAS号 化学式 分子量

反应信息

点击查看最新优质反应信息

文献信息

  • Synthesis and biological evaluation of cis-restrained carbocyclic combretastatin A-4 analogs: Influence of the ring size and saturation on cytotoxic properties
    作者:Christina Nowikow、Rita Fuerst、Maria Kauderer、Christian Dank、Walther Schmid、Marian Hajduch、Jiri Rehulka、Sona Gurska、Olena Mokshyna、Pavel Polishchuk、István Zupkó、Petr Dzubak、Uwe Rinner
    DOI:10.1016/j.bmc.2019.07.048
    日期:2019.10
    physiological conditions, reducing the overall activity of the drug candidates. Herein, we report the preparation of cis-restrained carbocyclic analogs of CA-4. The compounds, which differ by the size and hybridization of the carbocyclic ring have been evaluated for their cytotoxic properties and their ability to inhibit tubulin polymerization. Biological data, supported by molecular docking studies, identified
    Combretastatin A-4(CA-4)是一种高度细胞毒性的天然产物,已经制备了几种衍生物,并已进行了临床试验。这些研究表明,天然产物的顺式-lb部分在生理条件下易于进行顺式/反式异构化,从而降低了候选药物的总体活性。在这里,我们报告顺式的制备约束的CA-4碳环类似物。已经评估了因碳环的大小和杂交而异的化合物的细胞毒性和抑制微管蛋白聚合的能力。在分子对接研究的支持下,生物学数据确定了天然产物环丁烯基和环丁基生物是高度有前途的候选药物。
  • Design and synthesis of silicon-containing tubulin polymerization inhibitors: Replacement of the ethylene moiety of combretastatin A-4 with a silicon linker
    作者:Masaharu Nakamura、Daisuke Kajita、Yotaro Matsumoto、Yuichi Hashimoto
    DOI:10.1016/j.bmc.2013.09.046
    日期:2013.12
    Silicon-containing combretastatin analogs were designed, synthesized and evaluated for stability and biological activities. Among them, compound 31 exhibited strong tubulin polymerization-inhibitory activity and very potent tumor cell growth-inhibitory activity (IC50 = 0.007 μM) in MCF-7 cell proliferation assay. This compound also potently inhibited [3H]colchicine binding (90.7% inhibition at 3 μM)
    设计,合成和评估了含康普他汀类似物的稳定性和生物活性。其中,化合物31 在MCF-7细胞增殖试验中显示出强大的微管蛋白聚合抑制活性和非常有效的肿瘤细胞生长抑制活性(IC 50 = 0.007μM)。该化合物还有效抑制[ 3 H]秋水仙碱的结合(3μM时抑制率为90.7%)。这些活性与康普他汀A-4(CA-4)(1)相当。另外,化合物31在物理化学上比1更稳定。这些结果表明,连接基可以充当顺式碳-碳双键的生物等排体。
  • Novel 3,4,7-Substituted Benzofuran Derivatives Having Binding Affinity to κ-Opioid Receptor
    作者:Daisuke Nishiyama、Yuki Sakai、Haruka Sekiguchi、Hiroaki Chiba、Ryosuke Misu、Shinya Oishi、Nobutaka Fujii、Hiroaki Ohno
    DOI:10.1248/cpb.c16-00302
    日期:——
    A series of novel 3,4,7-trisubstituted benzofuran derivatives were synthesized, and their binding affinity to kappa- (KOR) and mu-opioid receptors (MOR) were evaluated. Several aryl ethers showed moderate binding activities to KOR (IC50=3.9-11 microM) without binding to MOR.
    合成了一系列新颖的3,4,7-三取代苯并呋喃生物,并评估了它们与κ-(KOR)和μ阿片受体(MOR)的结合亲和力。几种芳基醚对KOR表现出中等的结合活性(IC50 = 3.9-11 microM),而对MOR没有结合。
  • [EN] AROMATIC NITROGEN-CONTAINING 6-MEMBERED RING COMPOUNDS AND THEIR USE<br/>[FR] COMPOSÉS CYCLIQUES AROMATIQUES AZOTÉS À 6 CHAÎNONS ET LEUR UTILISATION
    申请人:MITSUBISHI TANABE PHARMA CORP
    公开号:WO2010030027A1
    公开(公告)日:2010-03-18
    The present invention provides aromatic nitrogen-containing 6-membered ring compounds having execellent PDE10 inhibitory activity. The present invention relates to an aromatic nitrogen-containing 6-membered ring compound represented by the following formula [I0] or a pharmaceutically acceptable salt thereof, a method for preparing the same, and use of said compounds for PDE10 inhibitors, and a pharmaceutical composition comprising said compounds as an active ingredient: Formula [I0] wherein: X1, X2 and X3 each independently are N or CH, and at least two of X1, X2 and X3 are N; A is *-CH=CH-, *-C(Alk)=CH-, *-CH2-CH2- or *-O-CH2- (* is a bond with R1); Alk is a lower alkyl group; Ring B is an optionally substituted nitrogen-containing aliphatic heterocyclic group; R1 is an optionally substituted nitrogen-containing heterocyclic group, a nitrogen-containing heterocyclic moiety of which is a moiety selected from the group consisting of quinoxalinyl, quinolyl, isoquinolyl, quinazolinyl, pyrazinyl, pyrimidinyl and a moiety thereof fused with a 5 to 6-membered aliphatic ring thereto; Y0 is a group selected from the group consisting of the following (1) to (5): (1) an optionally substituted phenyl or an optionally substituted aromatic monocyclic 5 to 6-membered heterocyclic group; (2) an optionally substituted aminocarbonyl; (3) an optionally substituted amino lower alkyl; (4) -O-R2 wherein R2 is hydrogen, an optionally substituted lower alkyl, lower cycloalkyl, aliphatic monocyclic 5 to 6-membered heterocyclic group, or Formula [AA]; (5) mono- or di-substituted amino; provided that, when Y0 is mono- or di-substituted amino, the nitrogen-containing heterocyclic moiety of R1 is not quinoxalinyl or quinolyl.
    本发明提供了具有出色的PDE10抑制活性的芳香氮含6元环化合物。本发明涉及以下式[I0]所代表的芳香氮含6元环化合物或其药学上可接受的盐,其制备方法,以及将所述化合物用作PDE10抑制剂,以及包含所述化合物作为活性成分的药物组合物:式[I0]其中:X1、X2和X3各自独立地为N或CH,并且至少两个X1、X2和X3为N;A为*-CH=CH-,*-C(Alk)=CH-,*-CH2- -或*-O- -(*为与R1的键);Alk为低碳烷基基团;环B为可选择取代的含氮脂肪杂环基团;R1为可选择取代的含氮杂环基团,其中的氮杂环基团为从喹喔啉基,喹啉基,异喹啉基,喹唑啉基,吡嗪基,嘧啶基中选取的基团,或者与其中的5至6元脂环融合的基团;Y0为从以下(1)到(5)组成的基团:(1)可选择取代的苯基或可选择取代的芳香单环5至6元杂环基团;(2)可选择取代的基羰基;(3)可选择取代的基低碳烷基;(4)-O-R2其中R2为氢,可选择取代的低碳烷基,低环烷基,脂肪单环5至6元杂环基团,或式[AA];(5)单取代或双取代基;但是,当Y0为单取代或双取代基时,R1的含氮杂环基团不是喹喔啉基或喹啉基。
  • Synthesis, in vitro and in vivo evaluation of new hybrids of millepachine and phenstatin as potent tubulin polymerization inhibitors
    作者:Baijiao An、Shun Zhang、Jun Yan、Ling Huang、Xingshu Li
    DOI:10.1039/c6ob02507b
    日期:——
    In this paper, a series of millepachine derivatives were synthesized and evaluated as tubulin polymerization inhibitors. The optimal compound 5i, (3-hydroxy-4-methoxyphenyl)(5-methoxy-2,2-dimethyl-2H-chromen-8-yl)methanone, displayed the highest cytotoxicity toward a series of cancer cells (ranging from 18 to 45 nM of IC50). Further investigation revealed that 5i significantly repressed the multidrug
    本文合成了一系列Millepachine衍生物,并作为微管蛋白聚合抑制剂进行了评估。最佳化合物5i(3-羟基-4-甲氧基苯基)(5-甲氧基-2,2-二甲基-2 H-基-8-基)甲酮对一系列癌细胞具有最高的细胞毒性(范围从18至IC 50的45 nM )。进一步的研究表明5i可以显着抑制多药耐药细胞(A549 / CDDP,A2780 / TAX),并且对人正常细胞(HLF,BJ)的细胞毒性很小。细胞机制研究表明5i诱导G2 / M期停滞和凋亡,这与线粒体膜电位(MMP)的崩溃有关。此外,蛋白质印迹分析表明5i可以改变细胞周期相关蛋白(例如Cyclin B1,Cdc25c,Cdc2)和某些凋亡相关蛋白(例如Bax,Bad,Bcl-2,Bcl-1x)的平。最后,5i有效抑制了裸鼠中A549细胞的异种移植肿瘤的生长。
查看更多

同类化合物

(R)-3-(叔丁基)-4-(2,6-二异丙氧基苯基)-2,3-二氢苯并[d][1,3]氧杂磷杂环戊烯 (2S,3R)-3-(叔丁基)-2-(二叔丁基膦基)-4-甲氧基-2,3-二氢苯并[d][1,3]氧杂磷杂戊环 (2S,2''S,3S,3''S)-3,3''-二叔丁基-4,4''-二甲氧基-2,2'',3,3''-四氢-2,2''-联苯并[d][1,3]氧杂磷杂戊环 (2R,2''R,3R,3''R)-3,3''-二叔丁基-4,4''-二甲氧基-2,2'',3,3''-四氢-2,2''-联苯并[d][1,3]氧杂磷杂戊环 (2-氟-3-异丙氧基苯基)三氟硼酸钾 (+)-6,6'-{[(1R,3R)-1,3-二甲基-1,3基]双(氧)}双[4,8-双(叔丁基)-2,10-二甲氧基-丙二醇 麦角甾烷-6-酮,2,3,22,23-四羟基-,(2a,3a,5a,22S,23S)- 鲁前列醇 顺式6-(对甲氧基苯基)-5-己烯酸 顺式-铂戊脒碘化物 顺式-四氢-2-苯氧基-N,N,N-三甲基-2H-吡喃-3-铵碘化物 顺式-4-甲氧基苯基1-丙烯基醚 顺式-2,4,5-三甲氧基-1-丙烯基苯 顺式-1,3-二甲基-4-苯基-2-氮杂环丁酮 非那西丁杂质7 非那西丁杂质3 非那西丁杂质22 非那西丁杂质18 非那卡因 非布司他杂质37 非布司他杂质30 非布丙醇 雷诺嗪 阿达洛尔 阿达洛尔 阿莫噁酮 阿莫兰特 阿维西利 阿索卡诺 阿米维林 阿立酮 阿曲汀中间体3 阿普洛尔 阿普斯特杂质67 阿普斯特中间体 阿普斯特中间体 阿托西汀EP杂质A 阿托莫西汀杂质24 阿托莫西汀杂质10 阿托莫西汀EP杂质C 阿尼扎芬 阿利克仑中间体3 间苯胺氢氟乙酰氯 间苯二酚二缩水甘油醚 间苯二酚二异丙醇醚 间苯二酚二(2-羟乙基)醚 间苄氧基苯乙醇 间甲苯氧基乙酸肼 间甲苯氧基乙腈 间甲苯异氰酸酯